Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Non-Current Assets (2021 - 2025)

Krystal Biotech's Non-Current Assets history spans 5 years, with the latest figure at $309.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 1.47% year-over-year to $309.2 million; the TTM value through Dec 2025 reached $1.2 billion, up 14.91%, while the annual FY2025 figure was $309.2 million, 1.47% down from the prior year.
  • Non-Current Assets for Q4 2025 was $309.2 million at Krystal Biotech, down from $314.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $314.4 million in Q3 2025 and bottomed at $37.2 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $204.1 million (2023), against an average of $210.9 million.
  • The largest YoY upside for Non-Current Assets was 380.95% in 2022 against a maximum downside of 5.08% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $184.0 million in 2021, then decreased by 5.08% to $174.7 million in 2022, then soared by 31.93% to $230.4 million in 2023, then soared by 36.17% to $313.8 million in 2024, then decreased by 1.47% to $309.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Non-Current Assets are $309.2 million (Q4 2025), $314.4 million (Q3 2025), and $297.0 million (Q2 2025).